Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: A phase II trial in patients with hematologic malignancy

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 6, 2009, Pages 615-622

  McCune, J S ^a,b   Batchelder, A ^a   Guthrie, K A ^a   Witherspoon, R ^a,c   Appelbaum, F R ^a,c   Phillips, B ^a   Vicini, P ^c,d   Salinger, D H ^c,e   McDonald, G B ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CYCLOPHOSPHAMIDE;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; ENGRAFTMENT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY INJURY; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MALE; NEPHROTOXICITY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BAYES THEOREM; BILIRUBIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS, TOXIC; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 67349110797     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.27     Document Type: Article

References (22)

1. Santos, G.W. et al. Marrow transplantation in man following cyclophosphamide. Transplant. Proc. 3, 400-404 (1971).
2. Thomas, E.D. et al. Aplastic anaemia treated by marrow transplantation. Lancet 1, 284-289 (1972).
3. Thomas, E.D. et al. Cure of leukemia by marrow transplantation. Leuk. Res. 1, 67-70 (1977).
4. McDonald, G.B. et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann. Intern. Med. 118, 255-267 (1993).
5. DeLeve, L.D., Shulman, H.M. & McDonald, G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin. Liver Dis. 22, 27-42 (2002).
6. Fink, J.C., Cooper, M.A., Burkhart, K.M., McDonald, G.B. & Zager, R.A. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced "hepatorenal syndrome". J. Am. Soc. Nephrol. 6, 1655-1660 (1995).
7. Hingorani, S.R. et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int. 67, 272-277 (2005).
8. Gooley, T.A., Rajvanshi, P., Schoch, H.G. & McDonald, G.B. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology 41, 345-352 (2005).
9. de Jonge, M.E., Huitema, A.D., Beijnen, J.H. & Rodenhuis, S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br. J. Cancer 94, 1226-1230 (2006).
10. McDonald, G.B. et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101, 2043-2048 (2003).
11. DeLeve, L.D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24, 830-837 (1996).
12. McDonald, G.B. et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin. Pharmacol. Ther. 78, 298-308 (2005).
13. Salinger, D.H. et al. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin. Cancer Res. 12, 4888-4898 (2006).
14. Ringdén, O. et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 83, 2723-2730 (1994).
15. Geraci, J.P., Mariano, M.S. & Jackson, K.L. Radiation hepatology of the rat: microvascular fbrosis and enhancement of liver dysfunction by diet and drugs. Radiat. Res. 129, 322-332 (1992).
16. McDonald, G.B. Review article: management of hepatic disease following haematopoietic cell transplant. Aliment. Pharmacol. Ther. 24, 441-452 (2006).
17. Petersdorf, E.W. et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104, 2976-2980 (2004).
18. Ruutu, T. et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 100, 1977-1983 (2002).
19. Appelbaum, F.R., Forman, S.J., Negrin, R.S. & Blume, K.G. Thomas' Hematopoietic Cell Transplant 4th edn. (Blackwell, Malden, MA, 2009).
20. Qiu, R. et al. Diminishing the risk of nonrelapse mortality in hematopoietic stem cell transplantation: prediction of exposure to the cyclophosphamide metabolite carboxyethylphosphoramide mustard. Clin. Pharmacol. Ther. 76, 270-280 (2004).
21. Kahl, C. et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110, 2744-2748 (2007).
22. Sheiner, L.B. & Beal, S.L. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9, 503-512 (1981).